Zimbabwe has declined a significant American health deal worth $367m (£272m) spanning five years because of Washington's demand for confidential biological samples.
This move became public after a official document from December was leaked, which showed President Emmerson Mnangagwa felt the deal was "unbalanced".
A government spokesperson later stated that the US was requesting genetic material for scientific study and profit but was not willing to share the benefits from future vaccines.
"We are forced to start the challenging and unfortunate process of scaling back our health aid in Zimbabwe," remarked American envoy to Zimbabwe Pamela Tremont in a statement.
The US Embassy noted the United States had provided over $1.9bn for health programmes to Zimbabwe over the last twenty years.
A medical body in Zimbabwe has called for further talks to find a deal agreeable to both sides so the country's critical HIV treatment initiative can proceed.
Wider Context
This rejection follows a similar situation in Kenya, where a high court suspended a similar deal with the US after legal challenges were raised about the security of Kenyans' health data.
Since resuming the presidency last year, US President Donald Trump has slashed overseas assistance and closed the US Agency for International Development (USAID).
The agency had administered assistance for the American government, but Trump stated its spending was "wasteful" and his government was pursuing government-to-government deals to boost openness and accountability.
As per reports, 16 nations in Africa have so far agreed to these new health pacts, constituting over $18.3bn in new funding.
Details of the Declined Agreement
The funds for Zimbabwe was intended to gone towards "HIV/Aids treatment and prevention, tuberculosis, malaria, healthcare for mothers and children, and preparing for epidemics".
"We believe this collaboration could have provided immense advantages for the people of Zimbabwe, especially the 1.2 million currently on antiretroviral therapy through US-supported programmes," the Ambassador added.
However, government spokesperson Nick Mangwana maintained the arrangement was "unequal".
"The proposal required Zimbabwe to surrender its biological resources and data for a long time, without any corresponding assurance of access to any scientific breakthroughs – such as vaccines, diagnostics, or treatments – that could be developed from that shared data," his statement read.
"In essence, our country would provide the raw materials for scientific discovery without any certainty that the end products would be accessible to our people should a new disease outbreak emerge."
Sovereignty and International Frameworks
Mangwana further noted that the US's withdrawal from the World Health Organization (WHO) and its pursuit of one-on-one deals were undermining structures previously established through the global organization.
Mangwana cited its Pathogen Access and Benefit Sharing framework created to manage future global health emergencies.
"This mechanism is designed to guarantee that when a nation provides its data, the benefits – such as medicines and cures – are distributed fairly, not monopolised solely by those with the capability to create them."
These objections regarding the US deal "should not be misconstrued as opposition to America," Mangwana stressed.
"We are open to ongoing dialogue with our US partners on how subsequent co-operation might be designed in a manner that honours the independence and dignity of each country."
Medical Community Response
Medical experts stated it acknowledged the official position, but suggested that negotiations should continue considering much of the nation's Aids initiatives relied on external financing.
"In cases where specific concerns exist, such as those involving information security or implementation frameworks, these can often be resolved through detailed discussion and negotiated safeguards," it added.
The halted deal underscores the ongoing debate between receiving much-needed foreign assistance and safeguarding national sovereignty in an ever more data-driven world.